Associations between risk of mortality and atypical antipsychotic use in vascular dementia: A clinical cohort study

International Journal of Geriatric Psychiatry

Volumn 29, Issue 12, 2014, Pages 1249-1254

  Sultana, J ^a   Chang, C K ^b   Hayes, R D ^b   Broadbent, M ^b   Stewart, R ^b   Corbett, A ^a   Ballard, C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b King s College London   (United Kingdom)

Author keywords

Antipsychotics; Dementia; Mortality; Vascular

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; NEUROLEPTIC AGENT;

AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIINFARCT DEMENTIA; OUTCOME ASSESSMENT; PRESCRIPTION; RISK ASSESSMENT; DEMENTIA, VASCULAR; MULTIVARIATE ANALYSIS; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DEMENTIA, VASCULAR; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; RISK FACTORS;

EID: 84922464822     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4101     Document Type: Article

References (21)

1. Ballard C, Howard R. 2006. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 7(6): 492-500.
2. Ballard C, Hanney ML, Theodoulou M, et al. 2009. The dementia antipsychotic withdrawal trial (DARTAD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 8(2): 151-157.
3. Ballard C, Creese B, Corbett A, et al. 2011. Atypical antipsychotics for the treatment of behavioural and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opin Drug Saf 10(1): 35-43.
4. Barnes TR, Banerjee S, Collins N, et al. 2012. Antipsychotics in dementia: prevalence and quality of antipsychotic drug prescribing in UK mental health services. Br J Psychiatry 201(3): 221-226.
5. Chang CK, Hayes RD, Broadbent M, et al. 2010. All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study. BMC Psychiatry 10: 77.
6. Crugel M, Paton G, Singh P, et al. 2012. Antipsychotics in people with dementia: frequency of use and rationale for prescribing in a UK mental health service. Psychiatrist 36(5): 165-169.
7. Food and Drug Administration (FDA). 2005. FDA public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. [Internet] Available at: http://www.fda.gov/cder/drug/advisory/antipsychotics.htm. Accessed 13 August 2012.
8. Gill SS, Rochon PA, Herrmann N, et al. 2005. Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study. BMJ 330(7489): 445.
9. Hayes RD, Chang CK, Fernandes A, et al. 2011. Associations between substance use disorder sub-groups, life expectancy and all-cause mortality in a large British specialist mental healthcare service. Drug Alcohol Depend 118(1): 56-61.
10. Hoang U, Stewart R, Goldacre MJ. 2011. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ 343: d5422.
11. Kales HC, Valenstein M, Kim HM, et al. 2007. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 164(10): 1568-1576.
12. Laursen TM. 2008. Major psychiatric disorders increase risk of mortality. Evid Based Mental Health 11: 9.
13. National Institute for Health and Clinical Excellence (NICE). 2012. Dementia: Supporting people with dementia and their carers in health and social care [CG42]. Available at http://publications.nice.org.uk/dementia-cg42. Accessed 12 August 2013.
14. Owen MJ. 2012. Intellectual disability and major psychiatric disorders: a continuum of neurodevelopmental causality. BJP 200: 268-269.
15. Perry E, Ziabreva I, Perry R, et al. 2005. Absence of cholinergic deficits in "pure"vascular dementia. Neurology 64(1): 132-133.
16. Schneider LS, Dagerman KS, Insel P. 2005. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 294(15): 1934-1943.
17. Sink LS, Holden KS, Yaffe P. 2005. Risk of death with atypical antipsychotic drug treatment for dementia meta-analysis of randomized placebo-controlled trials. JAMA 294(15): 1934-1943.
18. StataCorp. 2011. Stata Statistical Software: Release 12. StataCorp LP: College Station, TX.
19. Steinberg M, Shao H, Zandi P, et al. 2008. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: Cache County Study. Int J Geriatr Psychiatry 23: 170-177.
20. Stewart R, Soremekun M, Perera G, et al. 2009. The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry 9: 51.
21. Tri firo G, Verhamme KM, Ziere G, et al. 2007. All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiol Drug Saf 16(5): 538-544.